Axovant initiated with an Outperform at Evercore ISI. Evercore ISI analyst Ravi Mehrotra initiated Axovant with an Outperform rating and a price targets of $3. The analyst believes that the company’s “pipeline of high-potential assets is not priced in to the stock”, with the Street view on the company as a “GT asset collector with no platform premium”. Mehrotra contends that Axovant’s lead asset AXO-Lenti-PD offers “promising preclinical data” with about 5-times more potency than predecessor ProSavin.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.